NCT05289193View on ClinicalTrials.gov

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

March 11, 2026

Study Completion Date

March 11, 2026

Conditions
MelanomaMelanoma Stage III
Interventions
DIAGNOSTIC_TEST

PET Scan

"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."

DRUG

Nivolumab

"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."

DRUG

Ipilimumab

"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."

PROCEDURE

Surgical Resection of Melanoma

"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER